Of interest, analysis of TCGA data shows that Gp78 can show both significantly elevated and reduced global expression in different cancer types as well as no significant changes in global Gp78 expression in multiple tumors, including breast cancer or sarcoma, the cancer of origin for the HT-1080 cell line. This evidence concerns the gene AMFR and sarcoma.